ATE206309T1 - Ligand für den c-kit-rezepten und verfahren zu seiner nutzung - Google Patents

Ligand für den c-kit-rezepten und verfahren zu seiner nutzung

Info

Publication number: ATE206309T1
Authority: AT; Austria
Prior art keywords: methods; kit ligand; applicants; antagonist; purified
Prior art date: 1992-04-23

Application number

AT93910645T

Other languages

English (en)

Inventor

Peter Besmer

Jochen Buck

Malcolm A S Moore

Karl Nocka

Original Assignee

Sloan Kettering Inst Cancer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-23

Filing date

1993-04-16

Publication date

2001-10-15

1993-04-16 Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer

2001-10-15 Application granted granted Critical

2001-10-15 Publication of ATE206309T1 publication Critical patent/ATE206309T1/de

Links

238000000034 method Methods 0.000 title abstract 4
239000003446 ligand Substances 0.000 title 1
102000015215 Stem Cell Factor Human genes 0.000 abstract 10
108010039445 Stem Cell Factor Proteins 0.000 abstract 10
239000005557 antagonist Substances 0.000 abstract 2
238000002648 combination therapy Methods 0.000 abstract 2
230000003394 haemopoietic effect Effects 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
230000000692 anti-sense effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
210000004602 germ cell Anatomy 0.000 abstract 1
210000003630 histaminocyte Anatomy 0.000 abstract 1
210000002752 melanocyte Anatomy 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
238000010188 recombinant method Methods 0.000 abstract 1
150000003384 small molecules Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/202—IL-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Oncology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)

AT93910645T 1992-04-23 1993-04-16 Ligand für den c-kit-rezepten und verfahren zu seiner nutzung ATE206309T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87396292A	1992-04-23	1992-04-23
PCT/US1993/003640 WO1993021936A1 (en)	1992-04-23	1993-04-16	LIGAND FOR THE c-KIT RECEPTOR AND METHODS OF USE THEREOF

Publications (1)

Publication Number	Publication Date
ATE206309T1 true ATE206309T1 (de)	2001-10-15

Family

ID=25362700

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93910645T ATE206309T1 (de)	1992-04-23	1993-04-16	Ligand für den c-kit-rezepten und verfahren zu seiner nutzung

Country Status (15)

Country	Link
US (1)	US6159461A (de)
EP (2)	EP0639979B1 (de)
JP (1)	JP3750819B2 (de)
KR (1)	KR100313064B1 (de)
AT (1)	ATE206309T1 (de)
AU (1)	AU675429B2 (de)
CA (1)	CA2133982C (de)
DE (1)	DE69330878T2 (de)
DK (1)	DK0639979T3 (de)
ES (1)	ES2168273T3 (de)
HK (1)	HK1041205A1 (de)
HU (1)	HU219540B (de)
PT (1)	PT639979E (de)
RU (1)	RU2180850C2 (de)
WO (1)	WO1993021936A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7144731B2 (en)	1989-10-16	2006-12-05	Amgen Inc.	SCF antibody compositions and methods of using the same
US6852313B1 (en)	1989-10-16	2005-02-08	Amgen Inc.	Method of stimulating growth of melanocyte cells by administering stem cell factor
US20050276784A1 (en) *	1990-08-27	2005-12-15	Solan-Kettering Institute For Cancer Research	Ligand for the c-kit receptor and methods of use thereof
US5525708A (en) *	1994-03-28	1996-06-11	Cytomed, Inc.	Covalent dimer of kit ligand
DE4412794A1 (de) *	1994-04-14	1995-12-14	Univ Ludwigs Albert	Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
PT793714E (pt) *	1994-11-16	2002-12-31	Amgen Inc	Utilizacao do factor de celulas estaminais e do receptor de interleucina 6 soluvel para a expansao ex vivo de celulas hematopoieticas multipotentes
AU741271B2 (en) *	1997-09-10	2001-11-29	Uab Research Foundation	Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
US6599710B1 (en)	1999-03-10	2003-07-29	The General Hospital Corporation	Treatment of autoimmune disease
US7572631B2 (en)	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
JPWO2002066069A1 (ja) *	2001-02-20	2004-09-24	関西ティー・エル・オー株式会社	炎症・腫瘍性疾患治療剤
US20030082806A1 (en) *	2001-04-27	2003-05-01	Xcyte Therapies, Inc.	Maturation of antigen-presenting cells using activated T cells
US7628988B2 (en)	2002-06-27	2009-12-08	The General Hospital Corporation	Methods and compositions for treating type 1 diabetes
US7582313B2 (en) *	2002-06-27	2009-09-01	The General Hospital Corporation	Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004072264A2 (en) *	2003-02-12	2004-08-26	Johns Hopkins University School Of Medicine	Fate determination by hes 1 in hematopoietic stem-progenitor cells and uses thereof
US20080102054A1 (en) *	2005-01-18	2008-05-01	Faustman Denise L	Compositions Containing Agm Cells And Methods Of Use Thereof
EP1722275B1 (de)	2005-05-10	2010-10-27	Agfa Graphics N.V.	Verfahren zur Verarbeitung von Flachdruckplatten
EP3936137A1 (de)	2013-02-07	2022-01-12	The General Hospital Corporation	Verfahren zur expansion oder abreicherung von t-regulatorischen zellen
CN111879948A (zh)	2013-10-17	2020-11-03	综合医院公司	鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
RU2563235C1 (ru) *	2014-07-29	2015-09-20	Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации	Способ увеличения пула стволовых клеток в организме
CN115043943A (zh)	2015-05-15	2022-09-13	综合医院公司	拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en)	2015-08-28	2019-05-09	The General Hospital Corporation	Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3355914B1 (de)	2015-09-29	2024-03-06	The General Hospital Corporation	Eine bcg-haltige zusammensetzung zur cholesterolsenkung.
US11859002B2 (en)	2016-05-13	2024-01-02	The General Hospital Corporation	Antagonistic anti-tumor necrosis factor receptor 2 antibodies
CN113302205B (zh)	2018-11-15	2024-12-06	综合医院公司	激动性肿瘤坏死因子受体超家族多肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991014757A1 (en) *	1990-03-28	1991-10-03	Nisshin Steel Co., Ltd.	Hot rolling lubricant for stainless steel
US5399493A (en) *	1989-06-15	1995-03-21	The Regents Of The University Of Michigan	Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
DK0423980T3 (da) *	1989-10-16	2000-10-09	Amgen Inc	Stamcellefaktor
WO1992000376A1 (en) *	1990-06-25	1992-01-09	Immunex Corporation	Mast cell growth factor
DE4026026A1 (de) *	1990-08-17	1992-02-20	Hoechst Ag	Acylaminomethyl-phosphinsaeuren und verfahren zur herstellung von acylaminomethanphosphonsaeuren und acylaminomethyl-phosphinsaeuren
US20030125519A1 (en) *	1990-08-27	2003-07-03	Peter Besmer	Ligand for the c-kit receptor and methods of use thereof
US5767074A (en) *	1990-08-27	1998-06-16	Sloan-Kettering Institute For Cancer Research	Compositions of soluble C-kit ligand and hematopoietic factors
WO1992006220A1 (en) *	1990-10-05	1992-04-16	President And Fellows Of Harvard College	Detection and isolation of ligands
WO1992018615A1 (en) *	1991-04-09	1992-10-29	Indiana University Foundation	System and process for supporting hematopoietic cells
US5199942A (en) *	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
US6001803A (en) *	1992-04-23	1999-12-14	Sloan-Kettering Institute For Cancer Research	Composition of c-kit ligand, GM-CSF, and TNF-α and method of use

1993
- 1993-04-16 DK DK93910645T patent/DK0639979T3/da active
- 1993-04-16 DE DE69330878T patent/DE69330878T2/de not_active Expired - Fee Related
- 1993-04-16 EP EP93910645A patent/EP0639979B1/de not_active Expired - Lifetime
- 1993-04-16 ES ES93910645T patent/ES2168273T3/es not_active Expired - Lifetime
- 1993-04-16 PT PT93910645T patent/PT639979E/pt unknown
- 1993-04-16 CA CA002133982A patent/CA2133982C/en not_active Expired - Lifetime
- 1993-04-16 RU RU94046426/14A patent/RU2180850C2/ru active
- 1993-04-16 AT AT93910645T patent/ATE206309T1/de not_active IP Right Cessation
- 1993-04-16 JP JP51932293A patent/JP3750819B2/ja not_active Expired - Fee Related
- 1993-04-16 EP EP01104932A patent/EP1127577A3/de not_active Withdrawn
- 1993-04-16 HU HU9403054A patent/HU219540B/hu not_active IP Right Cessation
- 1993-04-16 WO PCT/US1993/003640 patent/WO1993021936A1/en not_active Ceased
- 1993-04-16 AU AU41065/93A patent/AU675429B2/en not_active Ceased
1994
- 1994-10-24 KR KR1019940703793A patent/KR100313064B1/ko not_active Expired - Fee Related
1997
- 1997-07-23 US US08/898,982 patent/US6159461A/en not_active Expired - Lifetime
2002
- 2002-02-26 HK HK02101477.8A patent/HK1041205A1/en unknown

Also Published As

Publication number	Publication date
AU4106593A (en)	1993-11-29
RU2180850C2 (ru)	2002-03-27
ES2168273T3 (es)	2002-06-16
DE69330878D1 (de)	2001-11-08
KR950701226A (ko)	1995-03-23
WO1993021936A1 (en)	1993-11-11
EP1127577A3 (de)	2002-11-27
DE69330878T2 (de)	2002-05-29
AU675429B2 (en)	1997-02-06
EP0639979A4 (de)	1996-10-23
HU219540B (hu)	2001-05-28
DK0639979T3 (da)	2002-12-02
CA2133982C (en)	2008-02-12
KR100313064B1 (ko)	2002-04-06
CA2133982A1 (en)	1993-11-11
EP0639979B1 (de)	2001-10-04
JP3750819B2 (ja)	2006-03-01
HU9403054D0 (en)	1995-02-28
EP0639979A1 (de)	1995-03-01
PT639979E (pt)	2002-03-28
HK1041205A1 (en)	2002-07-05
HUT70696A (en)	1995-10-30
US6159461A (en)	2000-12-12
JPH07508721A (ja)	1995-09-28
RU94046426A (ru)	1997-01-10
EP1127577A2 (de)	2001-08-29

Legal Events

Date	Code	Title	Description
2002-11-15	UEP	Publication of translation of european patent specification
2011-01-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE206309T1 (de)	2001-10-15	Ligand für den c-kit-rezepten und verfahren zu seiner nutzung
HU9300541D0 (en)	1993-05-28	Ligand to receptor c-kit qnd method for its utilization
ATE344043T1 (de)	2006-11-15	Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung
GEP19981289B (en)	1998-05-01	Method for Preparing Preserved Medicinal Means Containing Human Protein and Medicinal Means
GEP20012413B (en)	2001-04-25	Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
ATE249422T1 (de)	2003-09-15	Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
ES2043890T3 (es)	1994-01-01	Nuevo uso medico.
DE3587939D1 (de)	1994-12-01	Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.
DE3482589D1 (de)	1990-08-02	Retro-inverse analoga des bradykinin-potentialisierenden peptids bpp-5a und verfahren zu ihrer herstellung.
DE69230112D1 (de)	1999-11-11	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DK0662827T4 (da)	2009-04-20	Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
MX9702380A (es)	1998-02-28	Nuevas carboxamidas con actividad antifungica.
DE3684409D1 (de)	1992-04-23	Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
DE69324671D1 (de)	1999-06-02	Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
CA2223433A1 (en)	1996-12-19	Ob protein compositions and methods
DE330227T1 (de)	1990-09-27	Loesliche t-4 derivate.
DE69625682D1 (de)	2003-02-13	Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DK12990A (da)	1990-03-16	Human granulocyt-makrofag-kolonistimulerende faktor og muteiner heraf
EP0306870A2 (de)	1989-03-15	Gamma-Interferon-Derivate, Herstellungsverfahren, Vektoren dafür und Arzneimittel daraus
ATE59295T1 (de)	1991-01-15	Prazosin-pirbuterol-mischung zur bronchendilatation.
AU643760B2 (en)	1993-11-25	Method and composition for increased skin concentration of active agents by iontophoresis
Lacombe et al.	1991	Spleen focus-forming virus long terminal repeat insertional activation of the murine erythropoietin receptor gene in the T3Cl-2 friend leukemia cell line.
UA5743C2 (uk)	1994-12-29	Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
EP0644768A4 (de)	1997-06-11	Verfahren und zusammensetzungen zur verhinderung von entzündungen, die durch endothelzellen und fibrinogen ausgelöst werden.
NZ334634A (en)	2000-08-25	Use of a protein extracted from mammalian liver for treating HIV